Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb reports positive new Yervoy trial data

Bristol-Myers Squibb reports positive new Yervoy trial data

7th June 2011

Bristol-Myers Squibb has published positive new trial data from the latest phase III study of its metastatic melanoma drug Yervoy.

The company has presented data at the American Society of Clinical Oncology annual meeting, which shows the drug's positive impact on overall survival rates among melanoma patients who had not received any previous treatment.

When trialled in combination with the chemotherapy regimen dacarbazine, Yervoy was shown to deliver a superior performance to dacarbazine alone, while safety results were demonstrated to be in line with previous studies.

The firm now aims to move ahead with another phase III study to evaluate an investigational 10 mg/kg dose to the US-approved 3 mg/kg regimen.

Dr Caroline Robert of the Institute Gustave Roussy in Paris said: "Results from this study are significant in a disease as devastating at metastatic melanoma."

Last month, Bristol-Myers Squibb received a recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for marketing authorisation for Yervoy in Europe.ADNFCR-8000103-ID-800569591-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.